CN1196784C - 人内皮特异受体基因的启动子及其用途 - Google Patents
人内皮特异受体基因的启动子及其用途 Download PDFInfo
- Publication number
- CN1196784C CN1196784C CNB981063500A CN98106350A CN1196784C CN 1196784 C CN1196784 C CN 1196784C CN B981063500 A CNB981063500 A CN B981063500A CN 98106350 A CN98106350 A CN 98106350A CN 1196784 C CN1196784 C CN 1196784C
- Authority
- CN
- China
- Prior art keywords
- nucleic acid
- sequence
- acid construct
- endothelium
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 101000881679 Homo sapiens Endoglin Proteins 0.000 title 1
- 108020003175 receptors Proteins 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims abstract 2
- 210000003038 endothelium Anatomy 0.000 claims description 52
- 108090000623 proteins and genes Proteins 0.000 claims description 39
- 108020004707 nucleic acids Proteins 0.000 claims description 23
- 102000039446 nucleic acids Human genes 0.000 claims description 23
- 150000007523 nucleic acids Chemical class 0.000 claims description 23
- 102000005962 receptors Human genes 0.000 claims description 20
- 239000012636 effector Substances 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 241000700605 Viruses Species 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 5
- 108090000695 Cytokines Proteins 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 230000022131 cell cycle Effects 0.000 claims description 5
- 230000004087 circulation Effects 0.000 claims description 5
- 238000011144 upstream manufacturing Methods 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 102000019034 Chemokines Human genes 0.000 claims description 4
- 108010012236 Chemokines Proteins 0.000 claims description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 4
- 102000013275 Somatomedins Human genes 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 230000004060 metabolic process Effects 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 230000009466 transformation Effects 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims description 3
- 206010039361 Sacroiliitis Diseases 0.000 claims description 3
- 208000007502 anemia Diseases 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 230000010261 cell growth Effects 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 238000005336 cracking Methods 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 239000000651 prodrug Substances 0.000 claims description 3
- 229940002612 prodrug Drugs 0.000 claims description 3
- 239000013598 vector Substances 0.000 claims description 3
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 230000006907 apoptotic process Effects 0.000 claims description 2
- 239000003114 blood coagulation factor Substances 0.000 claims description 2
- 230000003013 cytotoxicity Effects 0.000 claims description 2
- 231100000135 cytotoxicity Toxicity 0.000 claims description 2
- 239000003527 fibrinolytic agent Substances 0.000 claims description 2
- 230000003480 fibrinolytic effect Effects 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000002458 infectious effect Effects 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 244000052769 pathogen Species 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 claims description 2
- 239000013600 plasmid vector Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 3
- 241000282414 Homo sapiens Species 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract 1
- 230000003511 endothelial effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 32
- 239000000370 acceptor Substances 0.000 description 28
- 230000000694 effects Effects 0.000 description 28
- 210000003725 endotheliocyte Anatomy 0.000 description 15
- 102100036537 von Willebrand factor Human genes 0.000 description 15
- 210000002889 endothelial cell Anatomy 0.000 description 14
- 108010047303 von Willebrand Factor Proteins 0.000 description 14
- 229960001134 von willebrand factor Drugs 0.000 description 13
- 108091023040 Transcription factor Proteins 0.000 description 6
- 102000040945 Transcription factor Human genes 0.000 description 6
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 5
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 5
- 108091008605 VEGF receptors Proteins 0.000 description 4
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 4
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108091023043 Alu Element Proteins 0.000 description 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 101150045640 VWF gene Proteins 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 208000026037 malignant tumor of neck Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 101710176384 Peptide 1 Proteins 0.000 description 2
- 101800005149 Peptide B Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- 101100481404 Danio rerio tie1 gene Proteins 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102100037241 Endoglin Human genes 0.000 description 1
- 108010036395 Endoglin Proteins 0.000 description 1
- 102000011852 GATA2 Transcription Factor Human genes 0.000 description 1
- 108010075641 GATA2 Transcription Factor Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- 101100481406 Mus musculus Tie1 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- WQZGKKKJIJFFOK-PQMKYFCFSA-N alpha-D-mannose Chemical compound OC[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-PQMKYFCFSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19704301A DE19704301C1 (de) | 1997-02-06 | 1997-02-06 | Der Promotor des humanen Endoglingens und seine Verwendung für die Gentherapie |
| DE19704301.1 | 1997-02-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1203948A CN1203948A (zh) | 1999-01-06 |
| CN1196784C true CN1196784C (zh) | 2005-04-13 |
Family
ID=7819364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB981063500A Expired - Fee Related CN1196784C (zh) | 1997-02-06 | 1998-02-05 | 人内皮特异受体基因的启动子及其用途 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6103527A (enExample) |
| EP (1) | EP0857781A3 (enExample) |
| JP (1) | JPH11178A (enExample) |
| KR (1) | KR19980071084A (enExample) |
| CN (1) | CN1196784C (enExample) |
| AR (1) | AR011110A1 (enExample) |
| AU (1) | AU736724B2 (enExample) |
| BR (1) | BR9800563A (enExample) |
| CA (1) | CA2222981A1 (enExample) |
| CZ (1) | CZ289227B6 (enExample) |
| DE (1) | DE19704301C1 (enExample) |
| HU (1) | HUP9800247A3 (enExample) |
| PL (1) | PL324688A1 (enExample) |
| RU (1) | RU2230115C2 (enExample) |
| TR (1) | TR199800168A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19704301C1 (de) * | 1997-02-06 | 1998-03-26 | Hoechst Ag | Der Promotor des humanen Endoglingens und seine Verwendung für die Gentherapie |
| CZ121599A3 (cs) | 1998-04-09 | 1999-10-13 | Aventis Pharma Deutschland Gmbh | Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu |
| DE60013586T2 (de) | 1999-04-02 | 2005-02-03 | Hisamitsu Pharmaceutical Co., Inc., Tosu | Genexpressions-basensequenzen zur therapeutischen anwendung und heilmittel zur gentherapie |
| RU2295281C2 (ru) * | 2005-04-20 | 2007-03-20 | Федеральное государственное учреждение Научно-исследовательский институт детских инфекций, г.Санкт-Петербург | Способ оценки тяжести инфекционного поражения цнс у детей |
| RU2297848C2 (ru) * | 2005-05-11 | 2007-04-27 | Александр Веньяминович Иткес | Генно-инженерная конструкция vegf-ибмед (vegf-ibmed) |
| WO2009045370A2 (en) | 2007-09-28 | 2009-04-09 | Intrexon Corporation | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
| US20110172293A1 (en) | 2008-07-08 | 2011-07-14 | Fish Jason E | Methods and Compositions for Modulating Angiogenesis |
| WO2014123749A1 (en) | 2013-01-30 | 2014-08-14 | Board Of Regents Of The University Of Nebraska | Compositions and methods for treating complications associated with diabetes |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5466596A (en) * | 1992-08-25 | 1995-11-14 | Mount Sinai Hospital Corporation | Tissue specific transcriptional regulatory element |
| GB9506466D0 (en) * | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
| DE19704301C1 (de) * | 1997-02-06 | 1998-03-26 | Hoechst Ag | Der Promotor des humanen Endoglingens und seine Verwendung für die Gentherapie |
-
1997
- 1997-02-06 DE DE19704301A patent/DE19704301C1/de not_active Expired - Fee Related
-
1998
- 1998-02-04 AR ARP980100497A patent/AR011110A1/es unknown
- 1998-02-04 CZ CZ1998332A patent/CZ289227B6/cs not_active IP Right Cessation
- 1998-02-04 TR TR1998/00168A patent/TR199800168A2/xx unknown
- 1998-02-04 CA CA002222981A patent/CA2222981A1/en not_active Abandoned
- 1998-02-05 BR BR9800563A patent/BR9800563A/pt not_active IP Right Cessation
- 1998-02-05 CN CNB981063500A patent/CN1196784C/zh not_active Expired - Fee Related
- 1998-02-05 AU AU52931/98A patent/AU736724B2/en not_active Ceased
- 1998-02-05 EP EP98102014A patent/EP0857781A3/de not_active Withdrawn
- 1998-02-05 KR KR1019980003185A patent/KR19980071084A/ko not_active Ceased
- 1998-02-05 HU HU9800247A patent/HUP9800247A3/hu not_active Application Discontinuation
- 1998-02-05 RU RU98101849/13A patent/RU2230115C2/ru not_active IP Right Cessation
- 1998-02-05 JP JP10024524A patent/JPH11178A/ja not_active Withdrawn
- 1998-02-06 US US09/019,689 patent/US6103527A/en not_active Expired - Fee Related
- 1998-02-06 PL PL98324688A patent/PL324688A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU736724B2 (en) | 2001-08-02 |
| BR9800563A (pt) | 1999-06-29 |
| HUP9800247A2 (hu) | 1998-10-28 |
| CA2222981A1 (en) | 1998-08-06 |
| RU2230115C2 (ru) | 2004-06-10 |
| EP0857781A3 (de) | 2001-05-16 |
| CZ289227B6 (cs) | 2001-12-12 |
| HUP9800247A3 (en) | 2002-11-28 |
| CN1203948A (zh) | 1999-01-06 |
| JPH11178A (ja) | 1999-01-06 |
| MX9800981A (es) | 1998-08-30 |
| CZ33298A3 (cs) | 1998-08-12 |
| HU9800247D0 (en) | 1998-03-30 |
| DE19704301C1 (de) | 1998-03-26 |
| AR011110A1 (es) | 2000-08-02 |
| PL324688A1 (en) | 1998-08-17 |
| KR19980071084A (ko) | 1998-10-26 |
| EP0857781A2 (de) | 1998-08-12 |
| TR199800168A2 (xx) | 1998-08-21 |
| AU5293198A (en) | 1998-08-13 |
| US6103527A (en) | 2000-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1332748A (zh) | 分离的编码t细胞诱导因子(tif)的核酸分子,其编码蛋白及其应用 | |
| CN1150804A (zh) | 成纤维细胞生长因子-10 | |
| CN1236390A (zh) | 血管形成因子及其在治疗心血管疾病中的用途 | |
| CN1295617A (zh) | 血管生成因子－血管内皮细胞生长因子vegf的突变体 | |
| CN1196784C (zh) | 人内皮特异受体基因的启动子及其用途 | |
| CN1332801A (zh) | 结缔组织生长因子(ctgf)及应用方法 | |
| CN1225019A (zh) | Ii合成的抑制 | |
| CN1198186A (zh) | 趋化因子β－8的短形式 | |
| CN1468956A (zh) | 高效表达治疗肿瘤的抗体的重组病毒及其用途 | |
| WO1999055863A1 (fr) | Nouveau polypeptide, adnc le codant et son utilisation | |
| EP2264059A1 (en) | Polypeptides, cDNAs encoding the same and utilization thereof | |
| EP1652924A2 (en) | Polypeptide, cDNA encoding the same and use thereof | |
| CN1353754A (zh) | 用作TNF－α信号传导途径抑制物的TRAF2变体 | |
| CN1283695A (zh) | 一种食管癌相关新基因 | |
| JP2002508179A (ja) | ポリペプチド、ポリヌクレオチド及びその用途 | |
| CN1230222A (zh) | Ptx－敏感g蛋白、其制备和应用 | |
| CN1299823A (zh) | 新的人细胞因子、其编码序列及用途 | |
| CN1183959C (zh) | 抑瘤多肽tsf及其基因治疗载体组合物 | |
| JPWO2009013794A1 (ja) | インスリン分泌誘導剤及び膵臓β細胞増加促進剤 | |
| CN1313297A (zh) | 具有抑制癌细胞生长功能的新的人蛋白及其编码序列 | |
| CN1388132A (zh) | 诱导细胞凋亡蛋白、其编码序列及用途 | |
| US20030008356A1 (en) | Novel polypeptide, a cDNA encoding the same, and use of it | |
| HK1017713A (en) | Promoter of the human endoglin gene and its use | |
| CN1375503A (zh) | 雄激素受体复合物相关蛋白 | |
| CN1711280A (zh) | 人体内的生长激素变异及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Applicant after: Awentis Medicines Deutschland GmbH Applicant before: Hechester JSC |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: HOECHST AKTIENGESELLSCHAFT (DE) TO: AVENTIS PHARMACY (GERMANY)INTERNATIONAL CO., LTD. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1017713 Country of ref document: HK |
|
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |